The protective roles of GLP-1R signaling in diabetic nephropathy: Possible mechanism and therapeutic potential

Kidney International

Volumn 85, Issue 3, 2014, Pages 579-589

  Fujita, Hiroki ^a   Morii, Tsukasa ^a   Fujishima, Hiromi ^a   Sato, Takehiro ^a   Shimizu, Tatsunori ^a   Hosoba, Mihoko ^a   Tsukiyama, Katsushi ^a   Narita, Takuma ^a   Takahashi, Takamune ^b   Drucker, Daniel J ^c,d   Seino, Yutaka ^e   Yamada, Yuichiro ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

diabetic nephropathy; glucagon like peptide 1; oxidative stress

Indexed keywords

ALBUMIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; NITRIC OXIDE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DIABETIC NEPHROPATHIES; GLOMERULUS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; BLOOD VESSEL WALL; CELL EXPANSION; DISEASE ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GLOMERULUS CAPILLARY; PROTEIN DETERMINATION; PROTEIN FUNCTION; UPREGULATION; URINE LEVEL;

ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETIC NEPHROPATHIES; GLUCAGON-LIKE PEPTIDE 1; KIDNEY GLOMERULUS; MALE; MICE, INBRED C57BL; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84895190840     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.427     Document Type: Article

References (51)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
2. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454
3. Fujita H, Sakamoto T, Komatsu K et al. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 2011; 34: 1302-1308
4. Guzik TJ, Mussa S, Gastaldi D et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-1662
5. Satoh M, Fujimoto S, Haruna Y et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144-F1152
6. Soccio M, Toniato E, Evangelista V et al. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest 2005; 35: 305-314
7. Wardle EN. Cellular oxidative processes in relation to renal disease. Am J Nephrol 2005; 25: 13-22
8. Fujita H, Fujishima H, Morii T et al. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice. Hypertens Res 2012; 35: 213-220
9. Gorin Y, Block K, Hernandez J et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280: 39616-39626
10. Kitada M, Koya D, Sugimoto T et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52: 2603-2614
11. Kim JS, Diebold BA, Babior BM et al. Regulation of Nox1 activity via protein kinase A-mediated phosphorylation of NoxA1 and 14-3-3 binding. J Biol Chem 2007; 282: 34787-34800
12. Saha S, Li Y, Anand-Srivastava MB. Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats. Can J Physiol Pharmacol 2008; 86: 190-198
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
14. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic betacell. Diabetes 2004; 53: 5-13
15. Leech CA, Chepurny OG, Holz GG. Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. Vitam Horm 2010; 84: 279-302
16. Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44-49
17. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978
18. Fujita H, Fujishima H, Chida S et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 2009; 20: 1303-1313
19. Fujita H, Fujishima H, Takahashi K et al. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice. Metabolism 2012; 61: 1714-1724
20. Panjwani N, Mulvihill EE, Longuet C et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154: 127-139
21. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not? Endocrinology 2013; 154: 4-8
22. Van Vliet A, Baelde HJ, Vleming LJ et al. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001; 193: 256-262
23. Thallas-Bonke V, Thorpe SR, Coughlan MT et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-Alpha-dependent pathway. Diabetes 2008; 57: 460-469
24. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669
25. Kanetsuna Y, Takahashi K, Nagata M et al. Deficiency of endothelial nitricoxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 2007; 170: 1473-1484
26. Wang CH, Li F, Hiller S et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 2011; 108: 2070-2075
27. Daniel C, Schaub K, Amann K et al. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 2007; 56: 2982-2989
28. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97: 7667-7669
29. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2010; 30: 49-59
30. Scrocchi LA, Hill ME, Saleh J et al. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 2000; 49: 1552-1560
31. Bengis-Garber C, Gruener N. Protein kinase A downregulates the phosphorylation of p47 phox in human neutrophils: a possible pathway for inhibition of the respiratory burst. Cell Signal 1996; 8: 291-296
32. Savitha G, Salimath BP. Cross-talk between protein kinase C and protein kinase A down-regulates the respiratory burst in polymorphonuclear leukocytes. Cell Signal 1993; 5: 107-117
33. Ohshiro Y, Ma RC, Yasuda Y et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006; 55: 3112-3120
34. Evans JL, Goldfine ID, Maddux BA et al. Oxidative stress and stress-Activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622
35. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113: 1708-1714
36. Arcos MI, Fujihara CK, Sesso A et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol 2000; 279: F1060-F1066
37. Prabhakar S, Starnes J, Shi S et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18: 2945-2952
38. Mima A, Hiraoka-Yamomoto J, Li Q et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967-2979
39. Hendarto H, Inoguchi T, Maeda Y et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61: 1422-1434
40. Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978
41. Breyer MD, Bottinger E, Brosius FC 3rd et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45
42. Inada A, Kanamori H, Arai H et al. A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse. J Cell Physiol 2008; 215: 383-391
43. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 537-546
44. Lubec B, Hermon M, Hoeger H et al. Aromatic hydroxylation in animal models of diabetes mellitus. FASEB J 1998; 12: 1581-1587
45. Hansotia T, Baggio LL, Delmeire D et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53: 1326-1335
46. Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005; 54: 2628-2637
47. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004; 286: F590-F596
48. Takemoto M, Asker N, Gerhardt H et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805
49. Tanabe K, Lanaspa MA, Kitagawa W et al. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol Renal Physiol 2012; 302: F1151-F1160
50. Nicholas SB, Basgen JM, Sinha S. Using stereologic techniques for podocyte counting in the mouse: shifting the paradigm. Am J Nephrol 2011; 33(Suppl 1): 1-7
51. Fujita H, Kakei M, Fujishima H et al. Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice. Biochem Biophys Res Commun 2007; 363: 37-43.